Long Pentraxin 3 as a Predictive Marker of Mortality in Severe Septic Patients Who Received Successful Early Goal-Directed Therapy

Sun Bean Kim¹, Kyoung Hwa Lee¹, Ji Un Lee², Hea Won Ann¹, Jin Young Ahn¹, Yong Duk Jeon¹, Jung Ho Kim¹, Nam Su Ku¹, Sang Hoon Han¹, Jun Yong Choi¹, Young Goo Song¹, and June Myung Kim¹

1Department of Internal Medicine, Yonsei University College of Medicine, Seoul; 2Department of Internal Medicine, Infectious Diseases, Hongik Hospital, Seoul, Korea.

Purpose: Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successful initial resuscitation through early goal-directed therapy (EGDT).

Materials and Methods: A prospective cohort study was conducted among 83 severe sepsis patients with fulfillment of all EGDT components and the achievement of final goal. Plasma PTX3 levels were measured by sandwich ELISA on hospital day (HD) 0, 3, and 7. The data for procalcitonin, C-reactive protein and delta neutrophil index were collected by electric medical record. The primary outcome was 28-day all-cause mortality.

Results: 28-day all-cause mortality was 19.3% and the median (interquartile range) APACHE II score of total patients was 16 (13–19). The non-survivors (n=16) had significantly higher PTX3 level at HD 0 [201.4 (56.9–268.6) ng/mL vs. 36.5 (13.7–145.3) ng/mL, \( p=0.008 \)]. PTX3 had largest AUC(ROC) value for the prediction of mortality among PTX3, procalcitonin, delta neutrophil index, CRP and APACHE II/SOFA sore at HD 0 [0.819, 95% confidence interval (CI) 0.677–0.961, \( p=0.008 \)]. The most valid cut-off level of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7%, specificity 73.8%). The PTX3 and procalcitonin at HD 0 showed strong correlation (r=0.675, \( p<0.001 \)). However, PTX3 at HD 0 was the only independent predictive marker in Cox’s proportional hazards model (≥140 ng/mL; hazard rate 7.16, 95% CI 2.46–15.85, \( p=0.001 \)).

Conclusion: PTX3 at HD 0 could be a powerful predictive biomarker of 28-day all-cause mortality in severe septic patients who have undergone successful EGDT.

Key Words: Pentraxin 3, severe sepsis, early-goal directed therapy, mortality, predictive biomarker

INTRODUCTION

Pentraxins are a superfamily of soluble multi-functional pattern recognition receptors.¹ Pentraxin 3 (PTX3) is the prototyp-
the targeted therapy according to the status of inflammatory response in each patient need to be developed to dramatically improve outcomes, especially in septic patients with high severity and risk of poor outcome. To achieve improvement, we must identify new prognostic biomarkers that can predict the mortality caused by severe sepsis, in spite of successful initial intensive resuscitation.6,9

Plasma PTX3 has been reported to be higher in patients with severe sepsis of high severity compared with healthy controls and patients with low severity sepsis.10–13 It has been suggested to be a good predictive marker of mortality in sepsis, because it may reflect tissue involvement by inflammatory processes more directly.1,14 However, there have been few studies to evaluate novel prognostic biomarkers including PTX3 to predict mortality in patients with severe sepsis receiving initial intensive resuscitation. The aim of this study, therefore, was to evaluate the relationship between PTX3 and poor outcome, and also to explore the role of PTX3 as a predictive biomarker of 28-day all-cause mortality in severe sepsis patients who received successful early goal-directed therapy (EGDT) and initial resuscitation according to Surviving Sepsis Campaign.6,15

MATERIALS AND METHODS

Study subjects and design

A prospective cohort study was conducted at Severance Hospital, a 2000-bed, tertiary-care, University-affiliated referral center located in Seoul, Republic of Korea. Total 474 patients visited at emergency department (ED) with presentation of the signs for systemic inflammatory response syndrome (SIRS) by infection from July 2012 and April 2013. The 199 patients were eligible if they were ≥20 years of age and had the sustained sepsis-induced hypotension or ≥4 mmol/L of lactate in spite of adequate initial fluid resuscitation (20–30 mL/kg) with crystalloid6,15,16 as well as receiving EGDT. We excluded 66 patients based on the following criteria: 1) pregnancy, 2) acute cerebrovascular accident, 3) acute coronary syndrome, 4) contraindication to central venous catheterization, 5) active gastrointestinal bleeding, 6) trauma, 7) drug overdose, 8) requirement of immediate surgery, and 9) do-not-resuscitate status. We prospectively enrolled 107 patients who had successfully undertaken EGDT, which was defined as the fulfillment of all EGDT components and achievement of the final goal of superior vena cava oxygen saturation (SvO₂) ≥70% within 6 hrs after arrival at the ED, as well as faithfully implemented EGDT and initial resuscitation of Surviving Sepsis Campaign international guidelines for management of severe sepsis and septic shock according to the recent update version at enrollment.6,15,17

We finally included total 83 participants in this prospective longitudinal study (Fig. 1). All participants were fulfilled with the definition for severe sepsis and septic shock.6,15,16

The primary outcome of this study was the 28-day all-cause mortality. Written informed consents were obtained from all patients before study enrollment. This study was approved by our local Ethic Committee of Institutional Review Board.

Data collection

The clinical characteristics and laboratory data of study participants were collected from electronic medical records. The clinical characteristics included age, gender, body mass index (BMI), primary infectious origin, underlying comorbidities, Charlson index,18 Sepsis-related Organ Failure Assessment (SOFA) score19 assessed upon arrival at the ED, acute renal / liver failure, bacteremia, methods for treatment of severe sepsis and appropriate initial empirical antibiotic use within 2 hrs from the arrival at the ED and the alive status on hospital day (HD) 0, 3, 7, 14, and 28. Acute Physiology and Chronic Health Evaluation II (APACHE II) score was assessed based on the worst values over the first 24 hrs of intensive care unit (ICU) care.20 Laboratory data included plasma procalcitonin (PCT; ng/mL), serum CRP (mg/L) and delta neutrophil index (DNI;
Definitions
HD 0 was defined as the time within 24 hrs after arrival at the ED. The other HDs were exactly calculated from HD 0 and consistently applied at all data collections and measurements of plasma PTX3. The survivors were defined as patients who were alive at HD 28 and the non-survivors were defined as patients who were dead by HD 28, irrespective of direct cause of death. The patients with any of the following criteria due to the infection were defined as severe sepsis; 1) sepsis-induced hypotension of systolic blood pressure (SBP) <90 mm Hg or MAP <70 mm Hg or SBP decrease >40 mm Hg, 2) lactate >4 mmol/L, 3) urine output <0.5 mL/kg/hr for ≥2 hrs despite adequate fluid resuscitation, 4) acute lung injury, 5) creatinine (Cr) increase >0.5 mg/dL, 6) bilirubin >4 mg/dL, 7) platelet <100000/μL, and 8) international normalized ratio (INR) >1.5.

Acute renal failure was diagnosed as an absolute increase in serum Cr of 0.3 mg/dL over 48 hrs or a 50% increase in Cr over 7 days according to Kidney Disease Improving Global Outcomes. Acute liver failure referred to the development of severe acute liver failure with encephalopathy and coagulopathy (INR ≥1.5) in a patient without prior known liver disease within 26 wks of the onset of any hepatic symptoms.

DNI is evaluated by subtracting the fraction of mature polymorphonuclear leukocytes from the sum of myeloperoxidase-reactive cells. Administration of low-dose steroid was defined as the use of intravenous hydrocortisone at a dose of 200 mg per day.

The measurement of plasma pentraxin 3 levels
Samples for PTX3 measurement were obtained from all living patients on HD 0, 3, 7, and 14. The plasma was stored at -70°C until analysis. PTX3 levels were measured by sandwiched ELISA, using a commercial kit of Human PTX3/TSG-14 Quantikine® Immunoassay (R&D Systems Inc., Minneapolis, MN, USA) with the detection limit of 0.1 ng/mL, according to the manufacturer’s instruction. We made the seven standard solutions (from 20 ng/mL to 0.313 ng/mL) by serial 1:2 dilution with zero standard (0 ng/mL) for standard curve. The optical densities were measured at 450 nm using the Spectramax® 190 microplate reader (Molecular Devices, Sunnyvale, CA, USA). Each sample including standard solution was tested in triplicate and the mean values were used in analyses. Both intra and interassay coefficients of variation were <10%. The PTX3 does not cross-react with short pentraxin of CRP and SAP.

Statistical analyses
Statistical analyses were performed using SPSS software, version 20 (SPSS Inc., Chicago, IL, USA) and a two-sided p value less than 0.05 was considered as statistically significant. All data for continuous variables were presented as median (interquartile range). Categorical variables were analyzed by χ² test or Fisher’s exact test, and continuous variables were analyzed by Mann-Whitney U test. The correlation between two continuous variables was evaluated by Pearson’s correlation coefficient (r). The differences in 28-day all-cause mortality by survival curve were compared using the log-rank test. The Cox’s proportional hazard model was computed to evaluate the independent predictive effect of initial PTX3 at HD 0 on 28-day all-cause mortality and to find the independent predictive variables of 28-day all-cause mortality with the variables with p values less than 0.05 in univariate analyses. The accuracy and cut-off levels of initial PTX3, PCT, and DNI for predicting 28-day all-cause mortality were investigated using receiver operating characteristic (ROC) curves. Area under the ROC curve (AUC) was expressed with 95% confidence interval (CI) and p value in each ROC curve.

RESULTS
The characteristics of study subjects
For the 83 enrolled subjects, the 28-day all-cause mortality was 19.3%. The number of patients who died on HD 3, 7, 14, and 28 was 5, 7, 13, and 16, respectively. The survivors (n=67) and non-survivors (n=16) were similar in age, gender, BMI and Charlson index including the frequency of various underlying comorbidities.

The APACHE II score was significantly higher in the non-survivors than in the survivors [20 (15–29) vs. 15 (12–19), p=0.011]. The frequency of acute liver failure in the non-survivors was significantly higher than that in the survivors (68.8% vs. 7.5%, p<0.001), but acute renal failure occurred at a similar frequency in the two groups. The most common primary infectious origin of severe sepsis was the urinary tract and lung in the survivors (38.8%) and non-survivors (50%), respectively. The frequency of initial bacteremia concomitance was also not significantly different between the two groups (56.3% vs. 47.8%, p=0.588). Among the treatment modalities of severe sepsis according to
the Surviving Sepsis Campaign updated in 2008 and 2012, mechanical ventilation and vasopressin use were significantly more frequent in the non-survivors than with the survivors (37.5% vs. 10.4%, \( p=0.016 \) and 31.3% vs. 4.5%, \( p=0.006 \)). However, the frequencies of continuous renal replacement therapy, low-dose steroid treatment, norepinephrine use, and adminis-

### Table 1. Comparison of Clinical Characteristics and Sepsis Treatment between Survivors and Non-Survivors

| Characteristics                                      | Total (n=83) | Survivors (n=67) | Non-survivors (n=16) | \( p \) value |
|------------------------------------------------------|-------------|------------------|----------------------|--------------|
| Age                                                  | 71 (64–77)  | 71 (64–77)       | 70 (63–76)           | 0.599        |
| Male (%)                                             | 47 (56.6)   | 37 (55.2)        | 10 (62.5)            | 0.598        |
| BMI (kg/m\(^2\))                                    | 23 (20–26)  | 23 (20–25)       | 23 (21–26)           | 0.710        |
| Charlson index                                       | 3 (2–4)     | 3 (2–4)          | 4 (3–5)              | 0.106        |
| Underlying comorbidities                             |             |                  |                      |              |
| Diabetes mellitus                                    | 28 (33.7)   | 23 (34.3)        | 5 (31.3)             | 0.815        |
| Chronic kidney disease                               | 12 (14.5)   | 8 (11.9)         | 4 (25.0)             | 0.233        |
| Cardiovascular disease*                              | 18 (21.7)   | 14 (20.9)        | 4 (25.0)             | 0.741        |
| Cerebrovascular disease                              | 19 (22.9)   | 17 (25.4)        | 2 (12.5)             | 0.340        |
| Solid cancer                                         | 27 (32.5)   | 20 (29.9)        | 7 (43.8)             | 0.286        |
| SOFA score                                           | 8 (6–9)     | 8 (6–9)          | 8 (6–10)             | 0.490        |
| APACHE II score                                      | 16 (13–19)  | 15 (12–19)       | 20 (15–29)           | 0.011        |
| Acute kidney failure                                 | 42 (50.6)   | 34 (50.7)        | 8 (50.0)             | 0.100        |
| Acute liver failure                                  | 16 (19.3)   | 5 (7.5)          | 11 (68.8)            | <0.001       |
| Primary infectious origin†                           |             |                  |                      |              |
| Urinary tract                                        | 30 (36.1)   | 26 (38.8)        | 4 (25.0)             | 0.392        |
| Respiratory                                          | 29 (34.9)   | 21 (31.3)        | 8 (50.0)             | 0.242        |
| Intra-abdomen                                        | 27 (32.5)   | 23 (34.3)        | 4 (25.0)             | 0.564        |
| Bacteremia                                           | 41 (49.4)   | 32 (47.8)        | 9 (56.3)             | 0.588        |
| Treatment of severe sepsis                           |             |                  |                      |              |
| CRRT                                                 | 13 (15.7)   | 8 (11.9)         | 5 (31.3)             | 0.117        |
| Mechanical ventilation                               | 13 (15.7)   | 7 (10.4)         | 6 (37.5)             | 0.016        |
| Low-dose steroid                                     | 42 (50.6)   | 31 (46.3)        | 11 (68.8)            | 0.164        |
| Norepinephrine                                       | 69 (83.1)   | 56 (83.6)        | 13 (81.3)            | 1.000        |
| Vasopressin                                          | 8 (9.6)     | 3 (4.5)          | 5 (31.3)             | 0.006        |
| Appropriate empirical antibiotics use within 2 hr     | 73 (88.0)   | 58 (86.6)        | 15 (93.8)            | 0.678        |
| Components of EGDT                                    |             |                  |                      |              |
| CVP (mm Hg)                                          |             |                  |                      |              |
| 0 hr                                                 | 6 (4–10)    | 6 (3–9)          | 6 (4–11)             | 0.491        |
| 2 hr                                                 | 7 (5–10)    | 7 (5–9)          | 7 (4–11)             | 0.771        |
| 4 hr                                                 | 8 (5–11)    | 9 (5–11)         | 8 (5–11)             | 0.364        |
| 6 hr                                                 | 9 (6–12)    | 10 (6–12)        | 9 (5–11)             | 0.694        |
| MAP (mm Hg)                                          |             |                  |                      |              |
| 0 hr                                                 | 59 (50–69)  | 57 (50–68)       | 60 (56–71)           | 0.339        |
| 2 hr                                                 | 71 (62–81)  | 71 (62–79)       | 68 (61–85)           | 0.798        |
| 4 hr                                                 | 82 (75–91)  | 83 (75–92)       | 78 (67–85)           | 0.095        |
| 6 hr                                                 | 85 (78–93)  | 87 (79–96)       | 77 (64–87)           | 0.009        |
| \( S_{\text{SV}_{2}} \) (%)                         |             |                  |                      |              |
| 0 hr                                                 | 66 (58–72)  | 65 (59–71)       | 69 (54–76)           | 0.244        |
| 2 hr                                                 | 68 (61–73)  | 67 (62–71)       | 71 (61–74)           | 0.371        |
| 4 hr                                                 | 73 (61–78)  | 72 (60–77)       | 77 (64–86)           | 0.289        |
| 6 hr                                                 | 79 (71–87)  | 77 (69–84)       | 83 (75–89)           | 0.105        |
| Total hospital stay (days)                           | 16 (8–24)   | 17 (11–29)       | 8 (3–13)             | <0.001       |

BMI, body mass index; SOFA, sequential organ failure assessment; APACHE, acute physiology and chronic health evaluation; CRRT, continuous renal replacement therapy; EGDT, early goal-directed therapy; CVP, central venous pressure; MAP, mean arterial pressure; \( S_{\text{SV}_{2}} \), superior vena cava oxygenation saturation. Values are presented as the median (interquartile range) or number (percent). SOFA score was assessed upon arrival at the emergency department and APACHE II score was assessed based on the worst values over the first 24 hrs of intensive care unit care.

*Except essential hypertension, †Multiple selection was possible in one patient.
tretation of the appropriate initial empirical antibiotics within 2 hrs upon arrival at the ED were not different between the two groups. The detailed components of EGDT at 0, 2, 4, and 6 hrs were similar between the two groups, except for the MAP level at 6 hrs (Table 1).

Change of inflammatory markers at various hospital days
The levels of PTX3, PCT, CRP, and DNI continually decreased with time for all study subjects. In particular, only PTX3 presented with a consistent and significant difference for HD 0, 3, and 7 between the survivors and non-survivors. The non-survivors had a significantly higher PTX3 at HD 0, 3, 7, and 14 than the levels in the survivors [HD 0: 201.4 (56.9–268.6) ng/mL vs. 36.5 (13.7–145.3) ng/mL, p=0.008; HD 3: 66.4 (49.3–146.1) ng/mL vs. 10.5 (8.5–17.3) ng/mL, p=0.002; HD 7: 49.7 (25.8–163.6) ng/mL vs. 8.6 (7.7–11.8) ng/mL, p=0.003] (Fig. 2, Table 2). Comparing with the 28-day all-cause mortality by quartile of PTX3 at HD 0, the mortality rates were higher in the groups with greater levels of PTX3 (Q1: 9.5%, Q2: 5.0%, Q3: 19.0%, Q4: 38.1%, p=0.024). The PCT levels did not reveal any significant difference at all on HD 0, 3, and 7. The CRP levels showed significantly higher values in the non-survivors at only HD 7. The DNI values showed significantly higher levels in the non-survivors only at HD 0 (Table 2).

The cut-off levels of various markers measured at HD 0 for the prediction of 28-day all-cause mortality
For PTX3, PCT, DNI, and CRP at HD 0, the largest and smallest AUC values for the prediction of 28-day all-cause mortality were for PTX3 and CRP, respectively (0.819, 95% CI 0.677–0.961, p=0.008 and 0.564, 95% CI 0.400–0.728, p=0.456, respectively). The most valid cut-off level to predict the 28-day mortality of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7% and specificity 73.8%). In addition, the most appropriate cut-off points of DNI were 10.6% with the AUC values of 0.739 (95% CI 0.591–0.887, p=0.003) (sensitivity 68.8% and specificity 77.6%) (Fig. 3A). The AUC values of APACHE II and SOFA score for the prediction of 28-day all-cause mortality (0.765 and 0.591, respectively) were smaller than PTX3 (Fig. 3B).

Table 2. Comparison of Inflammatory Markers Measured on Hospital day 0, 3, and 7 between Survivors and Non-Survivors

| HD  | Total          | Survivors       | Non-survivors   | p value |
|-----|----------------|-----------------|-----------------|---------|
| PTX3 (ng/mL) |                |                 |                 |         |
| 0   | 51.6 (14.3–197.6) | 36.5 (13.7–145.3) | 201.4 (56.9–268.6) | 0.008 |
| 3   | 12.7 (8.7–34.1)   | 10.5 (8.5–17.3)   | 66.4 (49.3–146.1) | 0.002 |
| 7   | 8.9 (7.8–13.5)    | 8.8 (7.7–11.8)    | 49.7 (25.8–163.6) | 0.003 |
| Procalcitonin (ng/mL) |          |                 |                 |         |
| 0   | 9.9 (0.6–30.6)    | 7.8 (0.3–30.6)    | 17.4 (9.7–33.4)  | 0.114 |
| 3   | 8.2 (0.2–12.7)    | 5.2 (0.1–12.9)    | 4.5 (0.3–21.7)   | 0.909 |
| 7   | 0.6 (0.1–2.1)     | 0.6 (0.1–1.8)     | 1.6 (0.6–19.1)   | 0.113 |
| CRP (mg/L) |            |                 |                 |         |
| 0   | 106.1 (42.3–174.2) | 106.1 (35.4–169.2) | 117.0 (55.6–201.5) | 0.723 |
| 3   | 64.1 (23.6–156.7)  | 64.1 (27.7–156.7)  | 58.8 (45.9–236.1) | 0.634 |
| 7   | 36.3 (12.7–76.9)   | 35.3 (12.3–70.7)   | 102.5 (47.0–172.6) | 0.004 |
| DNI (%) |                |                 |                 |         |
| 0   | 6.1 (1.9–13.6)    | 5.1 (1.3–10.0)    | 14.3 (5.8–50.1)  | 0.003 |
| 3   | 0.8 (0.0–2.9)     | 0.8 (0.0–2.1)     | 2.3 (0.4–4.1)    | 0.224 |
| 7   | 1.6 (0.1–3.0)     | 1.2 (0.0–3.0)     | 1.8 (1.7–4.7)    | 0.145 |

PTX3, pentraxin 3; CRP, C-reactive protein; DNI, delta neutrophil index; HD, hospital day.
Values are presented as the median (interquartile range). The number of total participants who received the measurement of above four inflammatory markers were 83, 78, and 76 at HD 0, 3, and 7, respectively. In survivors, the inflammatory markers were measured in 67 patients at all HD 0, 3, and 7. In non-survivors, the number of patient who received the measurement of the inflammatory markers were 16, 11, and 9 at HD 0, 3, and 7, respectively.
died by HD 28, but only 6 (10.7%) patients among the 56 patients with PTX3 level lower than 140 ng/mL at HD 0 were dead by HD 28. The percentage of subjects with PTX3 level greater than 140 ng/mL at HD 0 was significantly higher in the non-survivors than in the survivors [68.8% (11 of 16) vs. 23.9% (16 of 67), *p* = 0.003].

**Short-term change in plasma PTX3 level**

We subtracted the PTX3 level at HD 3 from the PTX3 level at HD 0 to identify the effect of the short-term change in PTX3 level on mortality. These short-term changes in values were significantly lower in the survivors than in the non-survivors [-33.0 (-154.0 – 3.8) ng/mL vs. 84.9 (-5.4 – 259.3) ng/mL, *p* < 0.001] (Fig. 4B). The plasma PTX3 levels at HD 3 showed decreasing values compared to those at HD 0 in 55 of 67 (82.1%) patients in the survivors. On the other hand, 8 of 11 (72.7%) patients in the non-survivors had a short-term increase in PTX3 level. The 28-day cumulative survival rate was 80% (12 of 15) in patients with the short-term decrease in PTX3 level at HD 3 in spite of greater than 140 ng/mL level of PTX3 at HD 0. In addition, 11 of 12 (91.7%) patients with PTX3 less than 140 ng/mL at HD 0 were alive at HD 28 in spite of the short-term increase in PTX3 value at HD 3.

**DISCUSSION**

Our present results suggest that the plasma PTX3 level measured within 24 hrs upon arrival at the ED could be a powerful
predictive biomarker for 28-day all-cause mortality in severe septic patients who have undertaken successful EGDT and initial resuscitation. The PTX3 level at HD 0 was the only independent marker associated with 28-day all-cause mortality in Cox’s proportional hazards model. The patients with a PTX3 level greater than 140 ng/mL at HD 0 had a 7-fold HR, and the mortality of these patients was as high as 68.8% in spite of the achievement at final goal of EGDT.

The plasma PTX3 level was previously evaluated to identify the association with the severity and mortality or the prediction of development of bacteremia or septic shock, mainly in heterogeneous populations, including SIRS and/or severe sepsis and/or critically ill or febrile neutropenic hematologic patients. On the other hand, only a few studies on homogeneous infectious patients were performed to assess the role of PTX3 in severity or as a prognostic marker in patients with ventilator-associated pneumonia, community-acquired pneumonia, bacteremia, severe leptospirosis or severe meningococcal disease. In spite of various infectious and/or inflammatory conditions, almost all the studies have shown that a higher level of PTX3 was related to severity or mortality, as indicated by our data. However, our study is unique because of our approach in assessing the role of serial PTX3 for the prediction of the mortality in the severe septic patients who have undertaken successful initial resuscitation.

Physicians worldwide fight desperately against severe sepsis through implementation of the Surviving Sepsis Campaign guidelines to improve survival rate. The surviving sepsis campaign guidelines are currently a very important strategy for treating severe sepsis because many clinical trials using new therapeutic drugs have not resulted in an improvement in mortality. The critical aspects of the Surviving Sepsis Campaign are initial resuscitation, which prevents the occurrence of multi-organ failure within 6 hrs of arrival at the ED and is mainly performed through the process of EGDT. Therefore, the discovery of new prognostic markers and targeted therapy using new therapeutic drugs may be extremely important, especially in severe septic patients who are likely to die in spite of successful initial resuscitation. Considering such clinical importance, we explored whether PTX3 is an independent predictive marker of 28-day mortality in the severe septic patients who have undertaken successful EGDT.

The short-term change after HD 3 as well as initial PTX3 at HD 0 could be useful for predicting the 28-day mortality in specific conditions. These values were significantly higher in the non-survivors than in the survivors. Non-survivors had a high rate of short-term increase in PTX3, but almost all of the survivors had a decreasing pattern. The predictive role of initial PTX3 level at HD 0 for 28-day all-cause mortality was affected by short-term change after HD 3. The 28-day mortality was as low as 20% in patients with a decreased PTX3 after HD 3 in spite of PTX3 greater than 140 ng/mL at HD 0, which was the only independent predictive factor in Cox’s regression model. Therefore, if we assess both the PTX3 level at HD 0 and short-term PTX3 change after HD 3, we could most likely obtain useful information to predict 28-day all-cause mortality in severe septic patients who have undertaken successful EGDT.

Our data showed a strong correlation between PTX3 and PCT at HD 0 and 14, which is a well-known diagnostic and predictive biomarker for severity and mortality in sepsis. However, initial PCT level at HD 0 was not an independent predictive marker for 28-day mortality, contrary to common expectations. The AUC value of PCT at HD 0 was lowest among

### Table 3. The Correlation of PTX3 with Other Inflammatory Markers Measured in All Participants Who were Alive at Each HD

|        | r   | p value |
|--------|-----|---------|
| PTX3 and procalcitonin |     |         |
| 0      | 0.675 | <.001   |
| 3      | 0.261 | 0.437   |
| 7      | 0.343 | 0.010   |
| 14     | 0.757 | <.001   |
| PTX3 and CRP |     |         |
| 0      | 0.253 | 0.024   |
| 3      | 0.268 | 0.044   |
| 7      | 0.308 | 0.022   |
| 14     | 0.496 | 0.003   |
| PTX3 and DNI |     |         |
| 0      | 0.507 | <.001   |
| 3      | 0.911 | <.001   |
| 7      | 0.885 | 0.533   |
| 14     | 0.268 | 0.132   |
| PTX3 and APACHE II score at HD 0 |     |         |
| 0.242 | 0.042 |
| PTX3 at HD 0 and SOFA score |     |         |
| 0.390 | 0.001 |

PTX3, pentraxin 3; CRP, C-reactive protein; DNI, delta neutrophil index; APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; HD, hospital day. r refers to the Pearson’s correlation coefficient. SOFA score was assessed upon arrival at the emergency department and APACHE II score was assessed based on the worst values over the first 24 hrs of intensive care unit care. The number of patients at HD 0, 3, 7, and 14 were 83, 78, 76, and 70, respectively.

### Table 4. Independent Predictive Factors for 28-Day All-Cause Mortality in Severe Sepsis Patients Receiving Successful Early-Goal Directed Therapy

| Variables            | HR    | 95% CIs  | p value |
|----------------------|-------|----------|---------|
| ≥71 yrs              | 3.27  | 0.57–10.69 | 0.377   |
| Male                 | 1.19  | 0.29–2.31 | 0.958   |
| APACHE II score ≥16 point | 2.18 | 0.51–9.25 | 0.685   |
| Mechanical ventilation | 1.92 | 0.64–5.81 | 0.089   |
| Acute liver injury   | 1.28  | 0.43–3.79 | 0.888   |
| Vasopressin use      | 2.89  | 0.92–9.18 | 0.546   |
| PTX3 at HD 0 ≥140 ng/mL | 7.16 | 2.46–15.85 | 0.001   |
| DNI at HD 0 ≥10.6%   | 1.23  | 0.13–9.03 | 0.217   |

HR, hazard rate; CI, confidence interval; APACHE, acute physiology and chronic health evaluation; PTX3, pentraxin 3; DNI, delta neutrophil index; HD, hospital day.
PTX3 and DNI. Furthermore, we observed in the detailed patient description that there were obviously patients for whom PTX3 were helpful for predicting mortality, while PCT was not predictive: the patients who died due to severe sepsis from pneumonia had a high initial PTX3 level and increasing PTX3 level at HD 7, irrespective of very low continuous PCT levels. In addition, the short-term change in PCT after HD 3 or 7 did not have predictive value for 28-day all-cause mortality. To our best knowledge, there have been no published study to assess the usefulness of PCT under EGDT or initial resuscitation according to surviving sepsis campaign guidelines. Thus, further studies are warranted to identify any specific sepsis characteristics, such as the primary source of sepsis or specific clinical infectious circumstances, to establish the clinical utility of PTX3 as a biomarker for severe sepsis.

In the present study, we also evaluated the predictive role of DNI for 28-day mortality in severe septic patients who had undertaken successful EGDT and compared these values with PTX3. DNI, which are easily obtained as part of complete blood cell analysis and differential count can be determined without additional tests or additional cost, are new biomarkers for the prediction of severity and prognosis in sepsis. Nevertheless, there have been no published studies to evaluate these biomarkers in severe septic patients who have undertaken successful EGDT.

In addition to important characteristics and homogeneity of our study population, our present study has several strengths and is unique in its approach to evaluate the prognostic role of PTX3 for mortality in severe sepsis. It has consistently been reported that initially high plasma PTX3 levels are associated with mortality or fatality in patients with inflammation by infection, including severe sepsis. In the present study, we found much higher overall mean or median PTX3 at HD 0 than in previously reported studies (122.0 ng/mL in our study, 7.8 ng/mL in bacteremia patients by Huttunen, et al., and 16.7 ng/mL in 49 severe sepsis patients by Uusitalo-Seppälä, et al., 12 71.3 ng/mL in patients admitted to an ICU with SIRS by Bastrup-Birk, et al., 13). Our high overall initial PTX3 level was similar to 118 ng/mL in the subgroup analysis carried out by Bastrup-Birk, et al., 13. These findings, along with 19.3% of total 28-day all-cause mortality and 16.2 of total APACHE II score in our study, suggest that the severity of sepsis in our study population was as high as those in severe septic patients encountered during routine clinical practice, although a direct comparison was impossible because of the absence of an APACHE II score in other studies.

The cut-off point for the prediction of mortality was higher in our study than in previously reported studies (140 ng/mL in our study, 15 ng/mL by Huttunen, et al., 14 7.7 ng/mL by Uusitalo-Seppälä, et al., and 32.6 ng/mL by Bastrup-Birk, et al., 13). The AUC of PTX3 for the prediction of mortality in our study was as high as those in previously reported studies (0.819 in our study, 0.82 by Huttunen, et al., 15 and 0.69 by Uusitalo-Seppälä, et al.,). Mauri, et al. reported that the high PTX3 HD 5: HD 0 ratio may be associated with mortality in the 90 severe septic patients who were most similar to our study population among the studies for PTX3 and infection. In contrast to our study, however, the initial PTX3 levels in the study of Mauri, et al. were not different between non-survivors and survivors.

The main weakness of our study is relatively small number of enrolled study participants. We prospectively enrolled patients with an accurate definition of severe sepsis and successful achievement of EGDT, which is the core strategy of initial intensive resuscitation in the surviving sepsis campaign guidelines, and we obtained the results to suggest the powerful predictive role of initial PTX3. Therefore, our results have significant clinical relevance, and further studies for PTX3 are warranted, especially in septic patients with high severity and mortality irrespective of initial intensive resuscitation. Most recently, Cunha, et al. analyzed the association between the single-nucleotide polymorphisms in the PTX3 gene and the risk of invasive aspergillosis, and suggested an important role of PTX3 in critical
infectious diseases.

In conclusion, we found that the initial plasma PTX3 at HD 0 is a strong predictive biomarker for 28-day all-cause mortality of severe sepsis patients who have undergone successful EGDT. The PCT level at HD 0 has a strong correlation with PTX3, however, it cannot independently predict mortality. These findings suggest that PTX3 could play an important prognostic role in severe septic patients who received successful implantation of initial resuscitation.

REFERENCES

1. Bottazzi B, Garlanda C, Cotena A, Moalli F, Jaillon S, Deban L, et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 2009;227:9-18.

2. Hassady JD, Bascum R, Costa JJ, Fitzgerald T, Dubin W. Bacterial endotoxin is an active component of cigarette smoke. Chest 1999;115:829-35.

3. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992;267:22190-7.

4. Introna M, Alles VV, Castellano M, Picardi G, De Gioia L, Bottazzai B, et al. Cloning of mouse PTX3, a new member of the pentraxin gene family expressed at extrahapatic sites. Blood 1996;87:1862-72.

5. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2003;300:2323-9.

6. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-282.

7. Lee K, Chang Y, Song K, Park YY, Huh JW, Hong SB, et al. Associations between single nucleotide polymorphisms of high mobility group box 1 protein and clinical outcomes in Korean sepsis patients. Yonsei Med J 2016;57:111-7.

8. Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view. Mediators Inflam 2013;2013:165974.

9. Huttunen R, Aittoniemi J. New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis. J Infect 2011;63:407-19.

10. Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G, et al. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med 2008;36:2302-8.

11. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001;29:1404-7.

12. Uusitalo-Seppälä R, Huttunen R, Aittoniemi J, Koskinen P, Leino A, Vahlberg T, et al. Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: a prospective cohort study. PLoS One 2013;8:e53661.

13. Bastrup-Birk S, Skjøedt MO, Munthe-Fog L, Strom JJ, Ma YJ, Garred P. Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome. PLoS One 2013;8:e73119.

14. Kunes P, Holubcová Z, Kolackova M, Krejsk J. Pentraxin 3 (PTX 3): an endogenous modulator of the inflammatory response. Mediators Inflamm 2012;2012:926517.

15. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.

16. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003;29:530-8.

17. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.

18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.

19. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.

20. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.

21. Kang CL, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003;37:745-51.

22. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120:c179-84.

23. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology 2012;55:965-7.

24. Nahum CH, Choi JW, Lee J. Delta neutrophil index in automated immature granulocyte counts for assessing disease severity of patients with sepsis. Ann Clin Lab Sci 2008;38:241-6.

25. Huh JW, Choi HS, Lim CM, Koh Y, Oh YM, Shim TS, et al. Low-dose hydrocortisone treatment for patients with septic shock: a pilot study comparing 3 days with 7 days. Respirology 2011;16:1088-95.

26. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73.

27. Boyd JC. Mathematical tools for demonstrating the clinical usefulness of biochemical markers. Scand J Clin Lab Invest Suppl 1997;226:47-63.

28. Vänskä M, Koivula I, Hämäläinen S, Pulkki K, Nousiainen T, Juntunen E, et al. High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients. Haematologica 2011;96:1385-9.

29. Mauri T, Bellani G, Patroniti N, Coppadoro A, Peri G, Cuccovillo I, et al. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med 2010;36:821-9.

30. Lin Q, Fu F, Shen L, Zhu B. Pentraxin 3 in the assessment of ventilator-associated pneumonia: an early marker of severity. Heart Lung 2013;42:139-45.

31. Huttunen R, Hurme M, Aittoniemi J, Huhtala H, Vuento R, Laine J, et al. High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study. PLoS One 2011;6:e17653.

32. Wagenaar JF, Goris MG, Gasem MH, Ishandrio B, Moalli E, Mantovani A, et al. Long pentraxin PTX3 is associated with mortality and disease severity in severe Leptospirosis. J Infect 2009;58:425-32.
33. Sprong T, Peri G, Neeleman C, Mantovani A, Signorini S, van der Meer JW, et al. Pentraxin 3 and C-reactive protein in severe meningococcal disease. Shock 2009;31:28-32.
34. Kao SJ, Yang HW, Tsao SM, Cheng CW, Bien MY, Yu MC, et al. Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia. Clin Chem Lab Med 2013;51:907-13.
35. Vincent JL, Beumier M. Diagnostic and prognostic markers in sepsis. Expert Rev Anti Infect Ther 2013;11:265-75.
36. Seok Y, Choi JR, Kim J, Kim YK, Lee J, Song J, et al. Delta neutrophil index: a promising diagnostic and prognostic marker for sepsis. Shock 2012;37:242-6.
37. Park BH, Kang YA, Park MS, Jung WJ, Lee SH, Lee SK, et al. Delta neutrophil index as an early marker of disease severity in critically ill patients with sepsis. BMC Infect Dis 2011;11:299.
38. Kim CH, Park JT, Kim EJ, Han JH, Han JS, Choi JY, et al. An increase in red blood cell distribution width from baseline predicts mortality in patients with severe sepsis or septic shock. Crit Care 2013;17:R282.
39. Jo YH, Kim K, Lee JH, Kang C, Kim T, Park HM, et al. Red cell distribution width is a prognostic factor in severe sepsis and septic shock. Am J Emerg Med 2013;31:545-8.
40. Cunha C, Aversa F, Lacerda JF, Busca A, Kurzai O, Grube M, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med 2014;370:421-32.